Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021
Open Access
- 12 February 2021
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 325 (11), 1101-1102
- https://doi.org/10.1001/jama.2021.1967
Abstract
This JAMA Insights review provides clinical details of anaphylactic reactions reported to and verified by the CDC in the first month of use of the Pfizer-BioNTeKeywords
This publication has 8 references indexed in Scilit:
- Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021Morbidity and Mortality Weekly Report (MMWR), 2021
- Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 VaccineJAMA, 2021
- The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020Morbidity and Mortality Weekly Report (MMWR), 2021
- The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020Morbidity and Mortality Weekly Report (MMWR), 2020
- Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity — United States, January 26–October 3, 2020Morbidity and Mortality Weekly Report (MMWR), 2020
- Vaccine-associated hypersensitivityJournal of Allergy and Clinical Immunology, 2018
- Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)Vaccine, 2015
- Anaphylaxis: Case definition and guidelines for data collection, analysis, and presentation of immunization safety dataVaccine, 2007